MEDVi Weight Loss Results: How Much People Actually Lose

By the Weight Loss Provider Guide editorial team · Last verified: August 6, 2026 · How we researched this page

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

Affiliate disclosure: We may earn a commission if you use our MEDVi link. It does not change your price, and it did not change a single number on this page. You will see us contradict MEDVi's own marketing before we recommend anything.

The short version

MEDVi weight loss results are not as certain as the 18% headline makes them look. MEDVi says customers lose an average of 18% of their body weight during their first six months. MEDVi also says that number comes from weights customers report on forms—not a published clinical trial—and it does not publish the sample size, medication mix, dropout count, or method used when follow-up weights are missing.

Here is what has been measured outside MEDVi. In a 2025 real-world study of 7,881 adults with overweight or obesity, without type 2 diabetes, who started injectable semaglutide or tirzepatide in one large health system, the average loss after one year was 8.7%. People with no recorded treatment discontinuation averaged 11.9%. People who stopped within three months averaged 3.6%, and people who stopped between months three and twelve averaged 6.8%.

For a 200-pound starting weight, those four group averages equal about 17.4 pounds overall, 23.8 pounds with no recorded discontinuation, 7.2 pounds with early discontinuation, and 13.6 pounds with later discontinuation. Those are translations of study averages—not a personal range and not a MEDVi forecast.

So why might MEDVi's number look better? The public page does not tell us who is included when a six-month weight is missing. If a company calculates an average only from people who keep submitting weights, the average can rise because people who stop reporting disappear from the calculation. We cannot say MEDVi did that. We can say MEDVi has not published enough information to rule it out.

None of that means MEDVi is a bad choice. MEDVi may still fit a cash-paying adult who wants online access and understands the compounded route. It means you should sign up for the right reason—not because 18% sounds guaranteed.

Does MEDVi still sound like your kind of route?

→ Check MEDVi eligibility and current options

Medical approval is required. Before you pay, confirm the exact medication, dispensing pharmacy, recurring price, renewal date, and cancellation terms.

What do MEDVi weight loss results actually show?

MEDVi publishes three headline result figures: 15–20% average weight loss, 18% during the first six months, and 1–2 pounds per week after the first four weeks for a described subgroup. MEDVi says these figures come from weights customers report at intake and every three to four weeks—not from a clinical trial. That makes them MEDVi marketing benchmarks, not a verified prediction for one person.

Let's start with what MEDVi actually says, because most pages about MEDVi weight loss results repeat one number and move on.

We recorded the current result claims MEDVi displays on its own pages on August 6, 2026. Here they are in one place.

The MEDVi results claim ledger

Look down the sample-size column. Six current claims. Zero published sample sizes.

Now look at the time column. MEDVi attaches its six-month footnote to the 18%, 93%, and 6x block, but the separate 15–20% statement does not explain whether it uses the same patients, the same six-month window, or a different calculation.

A percentage needs a clock. Losing 18% in six months and losing 18% in eighteen months are not the same result.

What MEDVi does disclose about the data

MEDVi says customers report weight on the first medical intake form and then every three to four weeks. It says its site claims and benefits refer to self-reported data from customers on treatment plans that include compounded GLP-1 medications and clinician consultations. It also says the claims are not taken from clinical trials, studies, or public information.

That disclosure is useful. It tells us the number is MEDVi's internal customer report—not a blinded study, a verified scale program, or an FDA review.

What MEDVi does not disclose

MEDVi does not publish:

• How many people are behind each result
• Which medications were included
• How many used injections versus dissolvable tablets
• Which pharmacies filled the prescriptions
• The starting weights or health profiles of the group
• How many customers stopped treatment
• How many stopped submitting weights
• Whether 18% is a mean or a median
• The range of results
• How missing follow-up weights were handled
• Whether an outside party checked the data
• How “kept the weight off” was defined

Until those details are public, the 18% number cannot become a reliable personal expectation.

What “compounded” means, in plain words

A compounded medication is prepared by a compounding pharmacy or outsourcing facility instead of being sold as an FDA-approved finished drug from a manufacturer. FDA explains that compounded drugs are not FDA-approved. Compounding can meet a patient's specific clinical need, but the finished compounded product does not go through FDA approval, and FDA does not review it before sale for safety, effectiveness, or quality.

That is not a slur. Compounding is legal and can meet a real patient need. But it matters here because the famous 14.9% and 20.9% numbers came from trials of specific FDA-approved finished products—Wegovy and Zepbound—not from MEDVi's compounded products.

MEDVi now says this plainly in its own disclosures. It says its compounded medications are not FDA-approved or evaluated as finished products for safety, effectiveness, or quality.

So when you read “MEDVi patients lose 15–20%,” you are reading MEDVi's self-reported program claim. We found no published randomized clinical trial of MEDVi's compounded products.

What we actually verified

Verified on MEDVi's current pages: the 15–20%, 18%, 93%, 6x, 1–2-pound, and calculator claims; the self-report disclosure; the six-month footnote; the compounded-drug disclosure; the current cancellation language; the named pharmacy partners; and the prices displayed on several official MEDVi paths.

Not verified: MEDVi's raw patient records, the number behind the result claims, the missing-data method, a route-by-route outcome table, individual testimonial outcomes, or whether the reader's checkout price will match any public landing-page price.

What does the measured evidence actually show?

Trials of FDA-approved semaglutide and tirzepatide found mean losses of 14.9% at 68 weeks and up to 20.9% at 72 weeks. A 2025 real-world study of 7,881 adults with overweight or obesity and without type 2 diabetes who started injectable semaglutide or tirzepatide found 8.7% average loss at one year, with large differences by treatment continuation and maintenance dose. None of those studies tested MEDVi's compounded products.

This table puts MEDVi's number on the same page as results that were measured under clearer methods. It is context—not proof that the products are interchangeable.

Sit with the first two rows for a second.

MEDVi's six-month self-reported figure is higher than the 14.9% mean produced by FDA-approved semaglutide after 68 weeks in STEP 1. That does not prove MEDVi's number is false. It does mean the MEDVi number needs a very clear method before it deserves the same weight as a published trial.

The part nobody explains: who gets counted

Here is the question that can change an average more than almost anything else:

When a customer has no six-month weight, what happens to that person in the calculation?

MEDVi does not say.

There are several possible methods:

1. Count every starter and use a stated method for missing weights.
2. Count only people with a six-month weight.
3. Count only people still paying or still in treatment.
4. Carry an earlier weight forward.
5. Use another internal rule.

Those methods can produce different answers from the same group of people.

The real-world Cleveland Clinic study shows why this matters. More than 20% stopped within three months, another 32% stopped between months three and twelve, and about 48% had no recorded discontinuation by one year. The study did not treat the people who stopped as invisible: it reported their results separately.

This is not MEDVi data. It does not prove MEDVi loses track of people who stop. It proves why MEDVi must publish its missing-data and discontinuation method before a reader can understand the 18% average.

Think of a running club that advertises the average finish time only for runners who cross the finish line. The number may be mathematically correct, but it does not answer what happened to everyone who started.

Two more facts that change real-world results

Maintenance dose. In the 7,881-person real-world study, 80.8% were classified as using lower maintenance doses. The study defined lower doses as 1 mg or less for semaglutide and 7.5 mg or less for tirzepatide. People with no recorded discontinuation who reached higher maintenance doses averaged 13.7% loss with semaglutide and 18.0% with tirzepatide at one year.

Not everyone responds the same way. In STEP 1, 86.4% of participants taking semaglutide reached at least 5% weight loss at week 68. That means 13.6% did not reach 5%, even in a controlled trial of the FDA-approved product.

That is not failure. It is biology.

See what your own numbers say

Put in your starting weight, current weight, and time on treatment. The calculator shows your actual percentage change beside three clearly labeled reference points: MEDVi's provider-stated claim, published trial results for different FDA-approved products, and a real-world average.

Your entries stay in your browser. We do not store your weight, medication, or health answers.

→ Check my MEDVi result so far

Are MEDVi's 15–20%, 18%, and 93% claims trustworthy?

It is verified that MEDVi publishes these figures. It is not verified that they represent the typical new MEDVi customer, because MEDVi does not publish the sample size, medication mix, treatment discontinuation, missing-data method, or independent audit. The safe reading is “MEDVi reports,” not “MEDVi customers can expect.”

We are going to be careful here, because most pages either swallow the marketing whole or start throwing accusations. Neither helps you decide.

We sorted every result-related statement into six buckets.

Now the audit.

The 93% claim has a clock problem

MEDVi says “93% kept the weight off for good.” The footnote under the same block says the data covers MEDVi patients during their first six months of treatment.

A first-six-month treatment window cannot prove that weight stayed off “for good.” To support that wording, MEDVi would need to publish what “kept off” means, when treatment ended, how long people were followed afterward, how many were followed, and what happened to people with missing follow-up.

MEDVi publishes none of those details.

When stopping has been measured in a trial, substantial regain was common. In the STEP 1 extension, participants who stopped semaglutide regained about two-thirds of the weight they had lost during the following year. That study involved an FDA-approved product, not MEDVi's compounded treatment, but it shows why a lifelong maintenance claim needs actual off-treatment follow-up.

Where the 6x number could mathematically match another study

STEP 1 reported 14.9% mean loss with semaglutide and 2.4% with placebo plus lifestyle support.

14.9 ÷ 2.4 = 6.2.

That is a mathematical match to a “6x” headline. We cannot prove that is where MEDVi got its number, and we are not saying MEDVi copied it. MEDVi's page says its claims come from its own customers, yet it does not identify a separate diet-and-exercise comparison group. Without that group, the public cannot reproduce the comparison.

The one real drawback, said plainly

MEDVi does not guarantee results, does not bill insurance for its cash-pay compounded program, and does not publish an independently audited outcome study. If you want a company to check coverage, handle prior authorization paperwork, or focus only on FDA-approved finished drugs, MEDVi is the wrong door. Ro's free coverage checker or our FDA-approved GLP-1 provider comparison is the better place to begin.

But here is the reason MEDVi can still make sense: the compounded path is cash-pay and does not require prior authorization. You do not have to wait for an insurer to decide whether your plan covers weight-loss medicine. A clinician still has to decide whether treatment is appropriate, and you still need to verify the product, pharmacy, checkout price, and renewal terms.

That trade is worth making for some people. It is not worth making blindly.

Does that trade sound like your situation?

→ Check MEDVi eligibility and current options

Medical approval is required. Before paying, confirm the exact medication, dispensing pharmacy, recurring charge, renewal date, and cancellation method.

How long does MEDVi take to work?

MEDVi's 1–2-pound weekly benchmark begins after the first four weeks and applies only to a described self-reporting subgroup. MEDVi does not publish a full week-by-week curve. Trials of FDA-approved products used gradual dose increases, so a quiet first month does not prove treatment failed—and it is not a reason to change a dose on your own.

The single easiest way to misread MEDVi results is to compare an early starting period with a headline number from a later point.

The trial dose clocks—not a MEDVi dosing schedule

STEP 1 increased semaglutide over 16 weeks before participants reached 2.4 mg. SURMOUNT-1 used a 20-week dose-escalation period for tirzepatide.

Those are study protocols for FDA-approved products. They are not instructions for a MEDVi patient, and they do not prove that a compounded product follows the same schedule or produces the same result.

What the evidence can support, month by month

The price clock matters too

A fixed month-by-month cost table would look useful, but MEDVi's current official pages do not support one clean set of numbers.

On August 6, 2026:

• A MEDVi price-lock page showed $116 per month for semaglutide and $166 for tirzepatide near the top.
• Lower on that same page, MEDVi said the locked rates were $166 for semaglutide and $199 for tirzepatide.
• MEDVi's general program page said compounded semaglutide starts at $179 for the first month, while the refill field rendered as a variable rather than a number.
• MEDVi's Terms and Conditions say the final charge may change based on the prescribed medication and dispensing pharmacy.

Those statements do not line up. Do not build a twelve-month budget from the first price you see in an ad.

Want the current MEDVi price before you commit?

→ See our dated MEDVi price and refill audit

Then open the actual checkout far enough to see the recurring charge and save a dated screenshot before paying.

Where do your MEDVi results fall so far?

Your result starts with your own starting weight. Pounds changed divided by starting weight, multiplied by 100, gives the percentage used in the studies on this page. That number can organize a clinician conversation; it cannot diagnose a problem or tell you to change your dose.

Percentages are how studies report results, and almost nobody thinks in percentages. Here is the translation first.

This is arithmetic, not a prediction. Starting weight alone cannot tell you how you will respond.

The math:

• Pounds changed = starting weight − current weight
• Percentage changed = pounds changed ÷ starting weight × 100
• Average per week = pounds changed ÷ weeks on treatment

Check your MEDVi result so far

Enter:

• Your starting weight
• Your current weight
• How many weeks you have been on treatment
• Injection, dissolvable tablet, FDA-approved finished product, or “not sure”
• The medication name exactly as printed on your label
• Whether you have reached the current clinician-directed maintenance step
• Any missed or delayed doses, if you want them in your notes

The checker shows:

• Pounds changed
• Percentage changed
• Average weekly change
• A simple personal trend chart
• MEDVi's 18% claim, labeled provider-stated self-reported data
• STEP 1 and SURMOUNT-1, labeled trials of different FDA-approved finished products
• The 8.7% real-world average, labeled one-year observational data for FDA-approved injectable products
• A clear reminder that none of those reference points predicts your result

The checker does not recommend a dose, call your result normal or abnormal, diagnose a plateau, or tell you to stop treatment.

Your entries stay in your browser. Nothing is saved, and no account is required.

Your clinician check-in notes

The checker also builds a one-page summary you can print or paste into a patient message:

• Medication name exactly as printed on the label
• Injection or tablet
• Dispensing pharmacy
• Start date
• Weeks at the current clinician-directed dose
• Missed or delayed doses
• Appetite changes
• Weight trend
• Side effects or shipping concerns
• Questions for the clinician

→ Build my clinician check-in notes — free, browser-only, no account.

Do MEDVi's tablets work as well as the injections?

MEDVi sells weekly compounded injections and daily dissolvable tablets but publishes no head-to-head outcome study between them. MEDVi's current public product card does not identify the exact ingredient in the dissolvable tablet, so the first step is to confirm the medication and formulation on the prescription label. Do not assume a compounded tablet and an injection produce the same exposure or result.

This is where the evidence gap gets wider.

What is known

Semaglutide and tirzepatide are peptide drugs. Delivering peptide medication by mouth is difficult because the body can break it down and absorb little of it unless the formulation solves that problem.

FDA-approved oral semaglutide uses a product-specific absorption enhancer and strict administration directions. Foundayo contains orforglipron, a different small-molecule drug designed to be swallowed. Neither fact proves that a compounded dissolvable semaglutide or tirzepatide tablet works the same way.

What MEDVi has not published

MEDVi does not publish:

• A tablet-versus-injection outcome comparison
• Human absorption data for its current dissolvable product
• A clear ingredient name on the current public tablet card
• A route-specific version of the 18% claim
• A route-specific sample size
• A route-specific discontinuation rate

That means the page cannot honestly tell you that MEDVi tablets work as well as MEDVi injections.

The pending lawsuit connected to MEDVi's care chain

A federal complaint filed in Delaware on November 20, 2025 names OpenLoop Health Inc., Triad Rx Buyer LLC, and Triad Rx Inc. as defendants. The plaintiff alleges that compounded oral tirzepatide purchased through a MEDVi-related process lacked demonstrated absorption and did not work as represented.

MEDVi is not a defendant. The complaint contains allegations, not court findings. The defendants have disputed the claims and moved to dismiss or compel arbitration. The public docket shows activity through June 29, 2026, and we found no public final ruling on the merits as of August 6, 2026.

This lawsuit does not prove that MEDVi's current tablet is ineffective. MEDVi's public page does not even identify the current tablet ingredient clearly enough for us to say it is the same product. It does prove why the exact label, formulation, pharmacy, and evidence matter before you choose a dissolvable route.

The honest choice for a needle-averse reader

If needles are a dealbreaker, compare all three paths:

1. MEDVi's current compounded dissolvable option, after confirming the exact ingredient and pharmacy.
2. An FDA-approved oral semaglutide product with product-specific administration rules.
3. Foundayo, an FDA-approved oral small-molecule GLP-1 medicine.

Needle-free matters. Evidence matters too.

→ Compare FDA-approved oral GLP-1 options and current costs

What do real MEDVi customers say about their results?

Public MEDVi reports are mixed. Some people describe meaningful loss; others describe slow progress, plateaus, little change, or no change, along with separate service and billing complaints. These are unverified self-reports, so they show the range of questions and experiences—not what a typical patient will lose.

About these reports: We did not verify any writer's identity, prescription, dose, starting weight, or outcome. Do not use a testimonial to judge medical effectiveness or safety.

“Over these 6 months, I have lost about 25 pounds.”

— Public Reddit report. Unverified self-report.

“Lost around 12 lbs” after roughly two months.

— Reddit user DebuggingDave. Unverified self-report.

“I have lost nothing but time and money.”

— Reddit user ventura_dragonfly, describing dissolvable tablets. Unverified self-report.

That spread is the honest picture. Anyone showing only the first quote is selling.

What we counted on MEDVi's own testimonial page

On August 6, 2026, we counted every testimonial on MEDVi's main weight-loss page.

One named testimonial is from a customer who says he is excited for his weight-loss journey to begin. He had not started yet.

This does not make the service praise fake. It means the testimonial block is mostly evidence about staff and process—not measured weight loss.

What Trustpilot can and cannot tell you

As of August 6, 2026, MEDVi had a 4.4 out of 5 Trustpilot score across 14,344 reviews. Trustpilot identified the profile as claimed since January 2025 and showed a paid Trustpilot subscription. Its AI-generated summary, based on 11,642 recent reviews, emphasized responsive nurse practitioners, care coaches, appointments, and customer service while also noting some reports involving efficacy, receiving a different medication than requested, or no desired result.

That is a meaningful service signal. Support matters when someone has a prescription question, side effect, shipment problem, or billing issue.

It is not a clinical outcome study. Many visible reviews are marked “Invited,” and most of the praise is about the interaction rather than a documented starting weight, ending weight, and treatment period.

One more disclosure MEDVi makes about its own page

MEDVi says some site text, images, or media may be generated or enhanced with artificial intelligence. It says people in ads may be actors or models, and testimonial images may use models for patient privacy.

Using a model for privacy is not automatically a problem. The point is simpler: the face beside a testimonial is not proof of that person's medical result, and MEDVi tells you that.

Why am I not losing weight on MEDVi?

A flat scale does not identify the cause. Time at the current clinician-directed dose, missed treatment, administration errors, storage, the exact medication, other health factors, and individual response can all matter. No public MEDVi evidence ranks those causes, so do not let a website diagnose the problem or tell you to change a dose.

If you are a month or two in and the scale has barely moved, read this part slowly.

A slow start does not mean you failed. It also does not prove the medicine is fake, and it is not a reason to draw more into a syringe.

Here are the questions worth checking—not a ranked diagnosis.

1. How long have you used the current clinician-directed step?

The 7,881-person real-world study found that 80.8% used lower maintenance doses, and higher maintenance dosing was associated with greater one-year loss. That is a group-level observation about FDA-approved injectable products. It does not tell us why one MEDVi customer is not losing.

Write down the start date and how long you have used the current prescribed step. Ask the clinician whether enough time has passed to assess it.

2. What exact medication and formulation did you receive?

Check the prescription label, not the ad.

Record:

• Medication name
• Compounded or FDA-approved finished product
• Injection or dissolvable tablet
• Concentration on the label
• Dispensing pharmacy
• Date dispensed

MEDVi works with more than one pharmacy, and its current public tablet card does not name the ingredient.

3. Could there be an administration or measurement problem?

FDA has received reports of dosing errors with compounded injectable semaglutide. Some people confused milligrams, milliliters, and syringe units, and some errors led to hospitalization.

Do not solve that by guessing.

Ask the prescriber or dispensing pharmacist to confirm:

• The prescribed dose in milligrams
• The concentration printed on the label
• The exact liquid volume or syringe marking for the syringe supplied

Write the answer down. Do not change it yourself.

4. Were doses missed, delayed, or changed?

Record missed or delayed treatment, a medication switch, a pharmacy change, or a move from tablet to injection. These facts give the clinician a usable timeline instead of a vague “it is not working.”

5. Was the medicine shipped and stored as directed?

FDA says an injectable GLP-1 product that requires refrigeration should not be used if it arrives warm or without enough refrigeration because quality may be affected. If a shipment arrived hot, was delayed, or sat outside, contact the dispensing pharmacy for instructions. Do not guess.

6. Could you be responding less than average?

In STEP 1, 13.6% of semaglutide participants did not reach 5% loss by week 68. That was the FDA-approved product in a trial. Individual response varies even when the product and protocol are controlled.

That is not a moral failing. It deserves a real clinician conversation—not three more months of silently blaming yourself.

What to bring to that conversation

1. What exact medication and formulation am I taking?
2. Is the dose on my label the dose you intended?
3. Have I used this step long enough to assess it?
4. Did I measure or take it correctly?
5. Could another medication or health condition affect the plan?
6. Are my side effects relevant?
7. Was the shipment stored correctly?
8. What specifically do you recommend next?
9. When should we review the trend again?

→ Build my clinician check-in notes

There is deliberately no sign-up button here. If you are already a patient with a medical question, you need your clinician or pharmacist—not another checkout page.

Is MEDVi's money-back guarantee real?

MEDVi shows “MEDVi Guarantee” and money-back imagery in its marketing, but the current written cancellation policy says treatment results and effectiveness are not guaranteed. That policy does not offer a general refund just because the scale does not move. Cancellation must reach MEDVi at least 72 hours before the next billing date, and MEDVi accepts cancellation by email or patient-portal chat.

We read the documents a customer can verify today. Here is what they say.

Read the first two rows together.

A money-back badge is marketing. The current written policy says results are not guaranteed and does not promise your money back if you miss a weight-loss target.

That is the damaging admission. It is also the fact that saves a reader from enrolling under the wrong assumption.

What to save before you pay

Screenshot all of it. It takes ninety seconds and can prevent a fight later.

• The landing page and offer you saw
• The exact first charge
• The exact recurring charge
• Whether the plan prepays more than one month
• The medication and pharmacy shown
• The renewal date
• The cancellation method
• The cancellation confirmation
• Any support message that changes the price or treatment

If easy cancellation matters more than the lowest ad price, that is a legitimate priority.

MEDVi's public policy directs customers to email or patient-portal chat; it does not describe a one-click cancellation button.

→ Compare GLP-1 providers with easier cancellation paths

What happens to your weight if you stop MEDVi?

MEDVi has not published an off-treatment follow-up study. In the STEP 1 extension, people who stopped FDA-approved semaglutide regained about two-thirds of their prior loss within one year; in SURMOUNT-4, participants switched from tirzepatide to placebo gained an average of 14.0% from week 36 to week 88. These studies do not predict one MEDVi customer's outcome, but they show that substantial regain after stopping was common.

This question should reframe the decision.

Not: “Can I afford the first month?”

But: “What is my plan if treatment helps and I need a longer runway?”

What the withdrawal studies found

• STEP 1 extension: 327 participants in the extension lost 17.3% during treatment. One year after treatment stopped, they had regained 11.6 percentage points and remained 5.6% below baseline—about two-thirds of the prior loss regained.
• SURMOUNT-4: Participants first completed a 36-week tirzepatide lead-in. Those switched to placebo then gained an average of 14.0% from week 36 to week 88, while those who continued tirzepatide lost another 5.5% during that period.

Those are trials of FDA-approved products under defined protocols. They are not MEDVi compounded-product studies.

Why this matters before month one

MEDVi's “93% kept the weight off for good” claim does not publish off-treatment follow-up. The best public evidence we have from approved-product withdrawal trials says stopping can be followed by substantial regain.

That does not mean everyone must stay on one drug forever. It means the exit or maintenance plan belongs in the first clinician conversation, not as a surprise after the last shipment.

Ask:

• Is this being planned as short-term or ongoing treatment?
• What would make the clinician continue, change, or stop it?
• What is the maintenance plan if it works?
• What happens if the price changes or the medication is no longer available?
• What follow-up support remains after stopping?

Price the runway, not just the first box.

Are MEDVi's medications FDA-approved?

MEDVi's compounded medications are not FDA-approved. MEDVi also currently lists separate FDA-approved options, including Wegovy pill, Wegovy injection, and Zepbound injection, each shown as a $99 membership plus medication cost. On February 20, 2026, FDA issued a warning letter naming MEDVi, LLC over compounded-drug marketing; MEDVi responded that the reviewed site was run by an affiliate marketing agency and that the material was removed.

You need this distinction to understand every result on the page.

What FDA said about MEDVi

FDA's public warning letter is dated February 20, 2026 and was published March 3, 2026. It is addressed to MEDVi, LLC dba MEDVi at MEDVi's Newark, Delaware address.

FDA said it reviewed medvi.io in December 2025 and objected to:

• Product images that suggested MEDVi was the compounder when it was not
• Claims that described compounded products as having the same active ingredient as named FDA-approved products in a way FDA said implied approval or equivalence
• False or misleading promotion that caused the marketed compounded products to be misbranded under federal law

This was not a recall. FDA did not state that every MEDVi-linked shipment was contaminated, counterfeit, or ineffective. The letter addressed marketing and labeling claims.

What MEDVi said in response

In an April 8, 2026 statement, MEDVi said medvi.io was not its current medvi.org address, that an affiliate marketing agency controlled the disputed page, that MEDVi required the material to be removed, and that MEDVi itself had not received the letter.

FDA's public record names MEDVi, LLC and uses MEDVi's business address. MEDVi says the reviewed domain and copy belonged to an affiliate. Both records should be shown.

As of August 6, 2026, we found no FDA close-out letter in the public record. The current MEDVi pages no longer use the specific “same active ingredient as” claims quoted in FDA's warning letter and now state that MEDVi does not compound the medication and that compounded products are not FDA-approved.

FDA's standing guidance on compounded GLP-1 drugs

FDA says:

• Compounded drugs are not FDA-approved.
• FDA does not review them before sale for safety, effectiveness, or quality.
• A compounded drug should meet a patient need that cannot be met by an FDA-approved drug.
• Patients should obtain a prescription and use a state-licensed pharmacy.
• Some compounded semaglutide products may use salt forms that are different active ingredients from those in approved drugs.
• Telehealth marketers should not call compounded products generic versions, the same as approved products, FDA-evaluated, or clinically proven to produce the same result.

That last rule is why this page never treats a MEDVi compounded product as interchangeable with Wegovy or Zepbound.

The three pharmacies MEDVi currently lists

MEDVi currently names:

• Triad Rx — Daphne, Alabama
• RedRock Pharmacy — St. George, Utah
• Beaker Pharmacy & Compounding — McKinney, Texas

Which pharmacy fills an individual prescription can change. Check the actual prescription label. That is the only reliable answer for your order and one of the first facts to record if you are troubleshooting.

Who is MEDVi best for—and who should choose something else?

MEDVi may fit a cash-paying adult who wants online access, is comfortable considering a compounded medication after clinician review, and will verify the exact product, pharmacy, checkout price, and cancellation date. It is a poor fit for anyone who needs insurance support, wants only an FDA-approved finished product, expects a result guarantee, or wants an independently audited MEDVi outcome study.

We would rather lose the affiliate click here than have you pay for the wrong plan.

MEDVi may fit you if

• A clinician decides treatment is medically appropriate
• You understand that compounded finished products are not FDA-approved
• You prefer cash-pay access over an insurance process
• You will verify the exact medication and pharmacy
• You will save the recurring price and renewal date before paying
• You accept that results vary and are not guaranteed

MEDVi is probably not your best fit if

• You expect a guaranteed percentage of weight loss
• You need insurance or prior-authorization support
• You want a simple refund if the scale does not move
• You want only an FDA-approved finished product
• You need a published, independently audited MEDVi outcome study
• Conflicting public prices make you unwilling to rely on checkout verification
• You will not be able to track a renewal date and cancellation window

If the first list describes you better than the second, the next step is a medical eligibility check—not a purchase. A clinician reviews your information and decides whether treatment may be appropriate.

→ Start MEDVi's medical eligibility assessment

Before entering payment details, confirm the exact medication, dispensing pharmacy, recurring charge, renewal date, and how to cancel.

What do MEDVi results cost over time?

MEDVi does not currently present one consistent public cash price. On August 6, 2026, one official price-lock page showed $116/$166 near the top and $166/$199 lower on the same page, while MEDVi's general path said compounded semaglutide starts at $179. MEDVi's Terms also say the final charge may change with the prescribed medication and pharmacy, so the checkout—not a review article—must control your budget.

Here is the current price-source ledger.

This is not a small formatting issue. A $50 monthly difference becomes $600 over a year.

Do this before you pay:

1. Open the exact affiliate path you plan to use.
2. Continue until the recurring charge is shown.
3. Confirm whether the price covers one month or several months.
4. Confirm the medication and formulation.
5. Confirm the dispensing pharmacy if shown.
6. Save a dated screenshot.
7. Ask support to explain any difference between the landing page and checkout in writing.

We do not give one fixed twelve-month MEDVi total because the public prices conflict. Build your budget from the recurring charge shown in your own checkout.

See the full MEDVi price and refill breakdown →

How we researched this page

This page separates MEDVi's own claims and policies from FDA records, primary clinical research, review-platform data, public court filings, and unverified customer reports. We did not test MEDVi's medication, access its internal patient data, verify any person's weight loss, or medically review an individual treatment plan.

What this page checked on August 6, 2026

• MEDVi's current weight-loss pages, claim blocks, footnotes, product cards, disclosures, and calculator
• MEDVi's Terms and Conditions, last updated March 31, 2026
• MEDVi's current Cancellation and Refund Policy
• All 19 testimonials visible on MEDVi's main weight-loss page
• STEP 1, the STEP 1 extension, SURMOUNT-1, and SURMOUNT-4
• Gasoyan et al.'s 2025 real-world cohort of 7,881 adults
• FDA's MEDVi warning letter and MEDVi's public response
• FDA's current compounded GLP-1 safety and promotion guidance
• MEDVi's current named pharmacy partners
• MEDVi's current Trustpilot score, review count, profile status, and review mix
• The public docket and complaint in Day v. OpenLoop Health Inc.
• Several current MEDVi price displays and the conflicting figures on one official page

What we could not verify

• MEDVi's raw outcome dataset
• The number of customers behind each headline claim
• The medication and route mix behind the 18% figure
• MEDVi's discontinuation rate
• MEDVi's missing-data method
• Whether 18% is a mean or median
• The exact current ingredient in MEDVi's public “GLP-1 Tablets” card
• The price every reader will see at checkout
• Any individual reviewer's identity, prescription, adherence, or result
• A final court ruling on the oral-tirzepatide complaint
• An FDA close-out letter for warning letter 721455

Twelve questions MEDVi would need to answer

We will publish a dated MEDVi response if one is received. Until then, these remain not publicly disclosed.

1. How many patients are behind each result figure?
2. What dates does the data cover?
3. Which medications and formulations are included?
4. Does each average include every person who started or only people with follow-up?
5. What percentage stopped treatment or stopped reporting weight?
6. Is 18% a mean or median?
7. What is the range or standard deviation?
8. How were missing follow-up weights handled?
9. What does “kept the weight off for good” mean, and how long was off-treatment follow-up?
10. What comparison group produced the 6x claim?
11. Has an outside party audited the dataset?
12. Do the 15–20%, 18%, and 1–2-pound figures describe the same group?

Who wrote this

This page was prepared by the Weight Loss Provider Guide editorial team. No clinician is listed as a medical reviewer because no clinician reviewed this page.

Corrections

We correct material errors when we find them or when a reader provides a better primary source. Commercial facts carry dates because prices, products, pharmacies, policies, and availability can change.

Update log

MEDVi weight loss results: frequently asked questions

How much weight can you lose with MEDVi in one month?

MEDVi does not publish a transparent first-month average. Its 1–2-pound weekly benchmark begins after week four and applies to a described self-reporting subgroup, so it should not be read as a promise of four to eight pounds in month one.

How long does MEDVi take to work?

MEDVi does not publish a week-by-week response curve. Its weekly benchmark begins after the first four weeks, while published trials of different FDA-approved products measured results over 68 or 72 weeks. If you are concerned about a slow start, ask the prescribing clinician to review your exact medication, timeline, and current prescribed step.

What are typical MEDVi results after three months?

MEDVi does not publish a sample size or a three-month outcome table. Calculate your own percentage trend and use it in a clinician conversation rather than treating one testimonial or the six-month 18% headline as your target.

What does MEDVi claim after six months?

MEDVi claims an average loss of 18% during the first six months. It does not publish enough method detail to show who was included, which treatment they used, or how missing weights were handled.

Is 1–2 pounds per week guaranteed?

No. MEDVi presents it as a self-reported average for a described subgroup, and MEDVi's current cancellation policy says treatment results and effectiveness are not guaranteed.

Is MEDVi's compounded semaglutide the same as Wegovy?

No. Wegovy is an FDA-approved finished drug. A compounded semaglutide product does not go through that product approval, and FDA has specifically warned telehealth marketers not to describe compounded drugs as the same as approved products.

Do MEDVi's tablets work as well as the injections?

MEDVi does not publish a head-to-head comparison, and its current public tablet card does not identify the exact ingredient. Verify the prescription label and pharmacy, and do not assume a compounded dissolvable tablet produces the same result as an injection.

Why am I not losing weight on MEDVi?

The scale alone cannot identify the cause. Time at the current prescribed step, the exact medication, administration, missed treatment, storage, other health factors, and individual response may matter. Contact the prescriber or dispensing pharmacist before changing anything.

Can I get a refund if MEDVi does not work?

MEDVi's current policy does not offer a general results-based refund. Monthly charges generally are not refunded for the current or past months; separate rules cover the first 72 hours before services, medical disqualification, and unshipped months on some multi-month plans.

Will I gain weight back if I stop?

No MEDVi-specific off-treatment study is published. In withdrawal studies of FDA-approved semaglutide and tirzepatide, substantial regain was common after treatment stopped. Discuss the maintenance or exit plan with the clinician before making a change.

Are MEDVi's medications FDA-approved?

MEDVi's compounded medications are not FDA-approved. MEDVi separately lists FDA-approved Wegovy pill, Wegovy injection, and Zepbound injection options at a $99 membership plus medication cost, with availability subject to change.

Which pharmacy fills MEDVi prescriptions?

MEDVi currently lists Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding. Check your actual prescription label because the pharmacy assigned to one order can differ from another.

What if my injection arrives warm?

FDA says not to use an injectable GLP-1 product requiring refrigeration if it arrives warm or without enough refrigeration. Contact the dispensing pharmacy or prescriber for instructions.

Is MEDVi available in every state?

MEDVi's terms say services are offered where available and do not publish one reliable current state list. Confirm availability for your state during the eligibility and checkout process before paying.

How do I report a serious side effect or product problem?

Contact the prescribing clinician and dispensing pharmacy. FDA also accepts adverse-event and product-quality reports through MedWatch. Call emergency services for a life-threatening reaction.

The bottom line on MEDVi weight loss results

MEDVi is a real telehealth platform that connects many people with clinician-reviewed weight-loss treatment. Its public service reviews show a real strength in staff access and support.

But the published MEDVi results numbers are self-reported, lack the method details needed for independent checking, and should not be treated like a clinical trial. Do not sign up because of 18%.

Sign up—if you do—because:

• A clinician says the treatment is appropriate
• You understand whether the product is compounded or FDA-approved
• Cash-pay online access fits your situation
• You verified the exact medication and pharmacy
• You saved the actual recurring price and renewal terms
• You accept that results are not guaranteed

That is a good reason. The 18% headline is not.

For a 200-pound person, the 2025 real-world study's one-year group averages translate to about 7.2 pounds after early discontinuation, 13.6 pounds after later discontinuation, 17.4 pounds overall, and 23.8 pounds with no recorded discontinuation. Those are not MEDVi results and not a personal range. They show why continuation, dose, product, and follow-up matter—and why one six-month marketing number cannot answer the whole question.

Ready to find out whether MEDVi fits?

A medical eligibility assessment is not a guarantee and not final approval. A clinician reviews your information and decides whether treatment may be appropriate.

→ Check current MEDVi options and eligibility

Confirm the exact medication, dispensing pharmacy, recurring charge, renewal date, and cancellation terms before paying.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz. It asks about insurance, budget, state, formulation preference, and whether needles are a dealbreaker—then gives you a personalized action plan.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. This page is for information only and is not medical advice. GLP-1 medications require a prescription and are not appropriate for everyone. Talk to a licensed clinician before starting, stopping, or changing treatment.

Sources

1. MEDVi weight-loss program page and disclosures — accessed August 6, 2026
2. MEDVi price-lock page — accessed August 6, 2026
3. MEDVi Terms and Conditions — last updated March 31, 2026
4. MEDVi Cancellation and Refund Policy — accessed August 6, 2026
5. MEDVi response to FDA warning-letter reporting — April 8, 2026
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 2021
7. Wilding JPH et al. STEP 1 trial extension, Diabetes, Obesity and Metabolism, 2022
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine, 2022
9. Aronne LJ et al. SURMOUNT-4 randomized withdrawal trial, JAMA, 2024
10. Gasoyan H et al. Changes in weight and glycemic control by discontinuation status, Obesity, 2025
11. Cleveland Clinic summary of the 7,881-person real-world study, June 10, 2025
12. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
13. FDA: What Telehealth Companies Should Know When Promoting Compounded Drugs
14. FDA Warning Letter 721455: MEDVi, LLC dba MEDVi, February 20, 2026
15. Trustpilot MEDVi profile — accessed August 6, 2026
16. Day v. OpenLoop Health Inc., complaint, D. Del. No. 1:25-cv-01418
17. Day v. OpenLoop Health Inc., Justia docket, D. Del. No. 1:25-cv-01418
18. Day v. OpenLoop Health Inc., CourtListener docket, D. Del. No. 1:25-cv-01418
19. Public Reddit report: six-month MEDVi experience
20. Public Reddit report: roughly two-month MEDVi experience
21. Public Reddit report: MEDVi dissolvable-tablet experience
22. Ro GLP-1 Insurance Coverage Checker — accessed August 6, 2026
23. Ro: How insurance works with the Ro Body membership — accessed August 6, 2026
24. FDA prescribing information for Wegovy tablets — accessed August 6, 2026
25. FDA prescribing information for Foundayo (orforglipron) — accessed August 6, 2026